Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.

Genetic testing and molecular biomarkers - 1 Jul 2016

Albitar Ferras, Ma Wanlong, Diep Kevin, De Dios Ivan, Agersborg Sally, Thangavelu Maya, Brodie Steve, Albitar Maher

Abstract excerpt

BACKGROUND: Demonstrating the presence of myelodysplastic syndrome (MDS)-specific molecular abnormalities can aid in diagnosis and patient management. We explored the potential of using peripheral blood (PB) cell-free DNA (cf-DNA) and next-generation sequencing (NGS). MATERIALS AND METHODS: We pe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to RUNX1 gene

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 27248906
DOI: 10.1089/gtmb.2015.0278

Genes

RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-27248906-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.PMID 27248906Read ↗

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA.Semantic proximity Read ↗

Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.Semantic proximity Read ↗

Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.Semantic proximity Read ↗

Myelodysplastic Syndrome: Diagnosis and ScreeningSemantic proximity Read ↗

Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Semantic proximity Read ↗

Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.Semantic proximity Read ↗

Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.Semantic proximity Read ↗

The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.Semantic proximity Read ↗

Monitoring molecular changes in the management of myelodysplastic syndromes.Semantic proximity Read ↗

Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndromeSemantic proximity Read ↗

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.